Compounds > ciprofloxacin

ciprofloxacin and guaifenesin

ciprofloxacin has been researched along with guaifenesin in 13 studies

Research

Studies (13)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (7.69)	18.2507
2000's	1 (7.69)	29.6817
2010's	10 (76.92)	24.3611
2020's	1 (7.69)	2.80

Authors

Authors	Studies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bregante, M; Gibson, I; McKellar, Q; Monteiro, A	1
De Lisle, RC; Norkina, O; Roach, EA	1
Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y	1
Sharma, V; Singh, B; Varshney, L	1
Günday Türeli, N; Juntke, J; Lehr, CM; Schneider, M; Schneider-Daum, N; Schwarz, BC; Torge, A; Türeli, AE	1
Beck, RCR; Chaves, PS; Guterres, SS; Oliveira, EG; Pohlmann, AR; Schneider, M; Titz, A; Torge, A; Wagner, S	1
Abisheganaden, JA; Chandrasekaran, R; Chotirmall, SH; Hadinoto, K; Koh, MS; Lim, AYH; Low, TB; Roizman, D; Tan, GL; Teo, J; Tran, TT; Vidaillac, C; Yong, VFL; Yu, H	1
Abisheganaden, JA; Chotirmall, SH; Hadinoto, K; Lim, AYH; Tran, TT; Vidaillac, C; Yu, H	1
Elgaher, WAM; Haupenthal, J; Hirsch, AKH; Lababidi, N; Ofosu Kissi, E; Rades, T; Schneider, M; Schwarz, BC; Sigal, V	1
de Souza Carvalho-Wodarz, C; Lababidi, N; Lehr, CM; Montefusco-Pereira, CV; Schneider, M	1

Reviews

1 review(s) available for ciprofloxacin and guaifenesin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

12 other study(ies) available for ciprofloxacin and guaifenesin

Article	Year
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:8 Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Bronchi; Cattle; Chromatography, High Pressure Liquid; Ciprofloxacin; Enrofloxacin; Exudates and Transudates; Fluoroquinolones; Inflammation; Injections, Subcutaneous; Male; Mucus; Quinolones	1999
Eradication of small intestinal bacterial overgrowth in the cystic fibrosis mouse reduces mucus accumulation. Journal of pediatric gastroenterology and nutrition, 2006, Volume: 42, Issue:1 Topics: Animals; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Female; Intestine, Small; Male; Metronidazole; Mice; Mice, Inbred C57BL; Mice, Inbred CFTR; Mucins; Mucus; Periodic Acid-Schiff Reaction; Reverse Transcriptase Polymerase Chain Reaction	2006
Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnology and bioengineering, 2011, Volume: 108, Issue:6 Topics: Administration, Inhalation; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Humans; Mannitol; Mucus; Pseudomonas aeruginosa; Pseudomonas Infections; Sodium Chloride	2011
Design of sterile mucoadhesive hydrogels for use in drug delivery: effect of radiation on network structure. Colloids and surfaces. B, Biointerfaces, 2014, Sep-01, Volume: 121 Topics: Adhesives; Animals; Ciprofloxacin; Differential Thermal Analysis; Diffusion; Drug Delivery Systems; Gamma Rays; Goats; Hemolysis; Hydrogels; Hydrogen-Ion Concentration; In Vitro Techniques; Microscopy, Electron, Scanning; Mucus; Particle Size; Povidone; Spectroscopy, Fourier Transform Infrared; Sterculia; Sterilization; Thermogravimetry; Thrombosis	2014
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2017, Volume: 117 Topics: Animals; Cell Line; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Horses; Humans; Lactic Acid; Mucus; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pseudomonas aeruginosa; Respiratory Mucosa; Respiratory Tract Infections	2017
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis. International journal of pharmaceutics, 2017, Jul-15, Volume: 527, Issue:1-2 Topics: Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Delayed-Action Preparations; Drug Carriers; Lipids; Mucus; Nanocapsules; Pseudomonas aeruginosa; Staphylococcus aureus	2017
A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart. International journal of pharmaceutics, 2018, Aug-25, Volume: 547, Issue:1-2 Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Case-Control Studies; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Delivery Systems; Dry Powder Inhalers; Excipients; Humans; Lactose; Lung; Mannitol; Mucus; Permeability; Pseudomonas aeruginosa	2018
An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis. International journal of pharmaceutics, 2019, Mar-25, Volume: 559 Topics: A549 Cells; Administration, Inhalation; Adult; Anti-Bacterial Agents; Bronchiectasis; Cell Line, Tumor; Ciprofloxacin; Dry Powder Inhalers; Epithelium; Humans; Liposomes; Lung; Mucus; Nanoparticles; Particle Size; Permeability; Powders; Pseudomonas aeruginosa; Young Adult	2019
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis. Journal of controlled release : official journal of the Controlled Release Society, 2019, 11-28, Volume: 314 Topics: Acetylcysteine; Administration, Inhalation; Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; Ciprofloxacin; Cystic Fibrosis; Drug Stability; Drug Storage; Expectorants; Horses; Mucus; Particle Size; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2019
Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2020, Volume: 157 Topics: Acetylcysteine; Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Ciprofloxacin; Curcumin; Cytokines; Drug Carriers; Drug Combinations; Drug Compounding; Expectorants; Freeze Drying; Humans; Inflammation Mediators; Macrophages; Microbial Viability; Mucus; Nanoparticles; Permeability; Polylactic Acid-Polyglycolic Acid Copolymer; Pseudomonas aeruginosa; Pseudomonas Infections; THP-1 Cells; Tobramycin	2020